Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Design of a liver cancer-specific selector for the analysis of circulating tumor DNA.

Sun Y, Meng R, Tang H, Wang H, Guo X, Ma Y, Yang Y, Wei X, Mu F, Wu G, Wang J, Liu J, Niu M, Xue J.

Oncol Lett. 2019 Jun;17(6):5369-5376. doi: 10.3892/ol.2019.10243. Epub 2019 Apr 12.

2.

Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.

Beije N, Helmijr JC, Weerts MJA, Beaufort CM, Wiggin M, Marziali A, Verhoef C, Sleijfer S, Jansen MPHM, Martens JWM.

Mol Oncol. 2016 Dec;10(10):1575-1584. doi: 10.1016/j.molonc.2016.10.001.

3.

The dynamic range of circulating tumor DNA in metastatic breast cancer.

Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C, Riethdorf S, Mauermann O, Lafer I, Pristauz G, Lax S, Pantel K, Geigl JB, Speicher MR.

Breast Cancer Res. 2014 Aug 9;16(4):421. doi: 10.1186/s13058-014-0421-y.

4.

Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy.

Ono A, Fujimoto A, Yamamoto Y, Akamatsu S, Hiraga N, Imamura M, Kawaoka T, Tsuge M, Abe H, Hayes CN, Miki D, Furuta M, Tsunoda T, Miyano S, Kubo M, Aikata H, Ochi H, Kawakami YI, Arihiro K, Ohdan H, Nakagawa H, Chayama K.

Cell Mol Gastroenterol Hepatol. 2015 Jun 17;1(5):516-534. doi: 10.1016/j.jcmgh.2015.06.009. eCollection 2015 Sep.

5.

[Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].

Li Y, Zhang FS, Guo L, Ying JM.

Zhonghua Bing Li Xue Za Zhi. 2018 Dec 8;47(12):904-909. doi: 10.3760/cma.j.issn.0529-5807.2018.12.002. Chinese.

PMID:
30522169
6.

Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer.

Beránek M, Sirák I, Vošmik M, Petera J, Drastíková M, Palička V.

Acta Medica (Hradec Kralove). 2016;59(2):54-8. doi: 10.14712/18059694.2016.54.

7.

Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.

Chen J, Chen J, He F, Huang Y, Lu S, Fan H, Wang M, Xu R.

Genet Test Mol Biomarkers. 2019 Apr;23(4):264-269. doi: 10.1089/gtmb.2018.0173.

PMID:
30986100
8.

Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.

Perets R, Greenberg O, Shentzer T, Semenisty V, Epelbaum R, Bick T, Sarji S, Ben-Izhak O, Sabo E, Hershkovitz D.

Oncologist. 2018 May;23(5):566-572. doi: 10.1634/theoncologist.2017-0467. Epub 2018 Jan 25.

9.

Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.

Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, Robinson M, Bitting RL, Thomas A, Alistar AT, Desnoyers RJ, Goodman M, Albright C, Porosnicu M, Vatca M, Qasem SA, DeYoung B, Kytola V, Nykter M, Chen K, Levine EA, Staren ED, D'Agostino RB Jr, Petro RM, Blackstock W, Powell BL, Abraham E, Pasche B, Zhang W.

J Hematol Oncol. 2017 May 4;10(1):100. doi: 10.1186/s13045-017-0468-1.

10.

Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.

Osumi H, Shinozaki E, Takeda Y, Wakatsuki T, Ichimura T, Saiura A, Yamaguchi K, Takahashi S, Noda T, Zembutsu H.

Cancer Med. 2019 Jan;8(1):408-417. doi: 10.1002/cam4.1913. Epub 2018 Dec 21.

11.

Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.

Chang YS, Fang HY, Hung YC, Ke TW, Chang CM, Liu TY, Chen YC, Chao DS, Huang HY, Chang JG.

J Cancer Res Clin Oncol. 2018 Nov;144(11):2167-2175. doi: 10.1007/s00432-018-2747-9. Epub 2018 Sep 10.

PMID:
30203147
12.

Next-generation sequencing of circulating tumor DNA for detection of gene mutations in lung cancer: implications for precision treatment.

Lai J, Du B, Wang Y, Wu R, Yu Z.

Onco Targets Ther. 2018 Dec 14;11:9111-9116. doi: 10.2147/OTT.S174877. eCollection 2018.

13.

Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.

Pécuchet N, Zonta E, Didelot A, Combe P, Thibault C, Gibault L, Lours C, Rozenholc Y, Taly V, Laurent-Puig P, Blons H, Fabre E.

PLoS Med. 2016 Dec 27;13(12):e1002199. doi: 10.1371/journal.pmed.1002199. eCollection 2016 Dec.

14.

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.

Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, Aggarwal C, Kosteva JA, Alley E, Ciunci C, Cohen RB, Bagley S, Stonehouse-Lee S, Sherry VE, Gilbert E, Langer C, Vachani A, Carpenter EL.

Clin Cancer Res. 2016 Dec 1;22(23):5772-5782. Epub 2016 Sep 6.

15.

The feasibility of using mutation detection in ctDNA to assess tumor dynamics.

Yi X, Ma J, Guan Y, Chen R, Yang L, Xia X.

Int J Cancer. 2017 Jun 15;140(12):2642-2647. doi: 10.1002/ijc.30620. Epub 2017 Mar 2. Review.

16.

Assessment of basal-like breast cancer by circulating tumor DNA analysis.

Wei W, Zhang X, Sun S, Xia B, Liang X, Cui Y, Gao S, Pang D.

Oncol Lett. 2018 May;15(5):7389-7396. doi: 10.3892/ol.2018.8224. Epub 2018 Mar 9.

17.

Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinoma.

Luo H, Li H, Hu Z, Wu H, Liu C, Li Y, Zhang X, Lin P, Hou Q, Ding G, Wang Y, Li S, Wei D, Qiu F, Li Y, Wu S.

Biochem Biophys Res Commun. 2016 Mar 18;471(4):596-602. doi: 10.1016/j.bbrc.2016.02.011. Epub 2016 Feb 12.

PMID:
26876573
18.

ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.

Ma F, Zhu W, Guan Y, Yang L, Xia X, Chen S, Li Q, Guan X, Yi Z, Qian H, Yi X, Xu B.

Oncotarget. 2016 Oct 4;7(40):66020-66031. doi: 10.18632/oncotarget.11791.

19.

Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients.

Cheng H, Liu C, Jiang J, Luo G, Lu Y, Jin K, Guo M, Zhang Z, Xu J, Liu L, Ni Q, Yu X.

Int J Cancer. 2017 May 15;140(10):2344-2350. doi: 10.1002/ijc.30650. Epub 2017 Mar 9.

20.

Detection of circulating tumor DNA in patients with osteosarcoma.

Barris DM, Weiner SB, Dubin RA, Fremed M, Zhang X, Piperdi S, Zhang W, Maqbool S, Gill J, Roth M, Hoang B, Geller D, Gorlick R, Weiser DA.

Oncotarget. 2018 Jan 18;9(16):12695-12704. doi: 10.18632/oncotarget.24268. eCollection 2018 Feb 27.

Supplemental Content

Support Center